Compare Quest Diagnostics Inc (DGX) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NIO Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while NIO Inc. trades at $5.03 (market cap $12.99B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.67% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| DGX | NIO | |
|---|---|---|
Market Cap | $22.80B | $12.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $7.89 |
52-Week Low | $166.42 | $4.11 |
Enterprise Value | $28.82B | $12.22B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
NIO trades at $4.93, up 3.14% today, but remains in a bearish technical trend with negative cash flows and persistent losses despite revenue growth to $87.49 billion in 2025. The company beat EPS estimates for three consecutive quarters, and June 2026 deliveries surged 62.9% year-over-year, indicating strong operational momentum. However, net income margin improved to -17.8% in 2025 but remains deep in negative territory, with a high debt load and substantial cash burn from operations.
Outlook is mixed: bullish delivery growth and analyst upgrades (Goldman Sachs to Buy, target $7) contrast with profitability risks and competitive EV market pressures. Investment appeal hinges on margin improvement and sustainable cash flow generation, while key risks include execution challenges, macroeconomic headwinds, and reliance on financing amid negative equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
